UA101172C2 - Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение - Google Patents

Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение

Info

Publication number
UA101172C2
UA101172C2 UAA201008616A UAA201008616A UA101172C2 UA 101172 C2 UA101172 C2 UA 101172C2 UA A201008616 A UAA201008616 A UA A201008616A UA A201008616 A UAA201008616 A UA A201008616A UA 101172 C2 UA101172 C2 UA 101172C2
Authority
UA
Ukraine
Prior art keywords
bicyclo
preparation process
pharmaceutical use
azo derivatives
substituted pyrazolon
Prior art date
Application number
UAA201008616A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пенг Чо Танг
Хеджун Лю
Хао Женг
Икян Чен
Хонгбо Фей
Шенглан Ванг
Ли Ванг
Original Assignee
Джянгсу Хенгруй Медисин Ко., Лтд.
Шанхай Хенгруй Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джянгсу Хенгруй Медисин Ко., Лтд., Шанхай Хенгруй Фармасьютикал Ко., Лтд. filed Critical Джянгсу Хенгруй Медисин Ко., Лтд.
Publication of UA101172C2 publication Critical patent/UA101172C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны бициклозамещенные пиразолоназопроизводные формулы (I) или их фармацевтически приемлемые соли, гидраты или сольваты, способы их получения, фармацевтические композиции, которые их содержат, и их применение в качестве терапевтического агента, особенно как миметиков тромбопоэтина (ТРО), и их применение в качестве агонистов рецептора тромбопоэтина.Значения заместителей в формуле (I) являются такими, как определено в описании.(I).
UAA201008616A 2008-01-10 2009-01-04 Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение UA101172C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2008100003466A CN101481352A (zh) 2008-01-10 2008-01-10 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PCT/CN2009/000001 WO2009092276A1 (zh) 2008-01-10 2009-01-04 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
UA101172C2 true UA101172C2 (ru) 2013-03-11

Family

ID=40878665

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201008616A UA101172C2 (ru) 2008-01-10 2009-01-04 Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение

Country Status (16)

Country Link
US (2) US8367710B2 (ru)
EP (1) EP2236500B1 (ru)
JP (1) JP5441269B2 (ru)
KR (1) KR101556808B1 (ru)
CN (2) CN101481352A (ru)
AU (1) AU2009207966B2 (ru)
BR (1) BRPI0907234B1 (ru)
CA (1) CA2711535C (ru)
ES (1) ES2533366T3 (ru)
HK (1) HK1134818A1 (ru)
MX (1) MX2010007553A (ru)
PT (1) PT2236500E (ru)
RU (1) RU2488582C2 (ru)
UA (1) UA101172C2 (ru)
WO (1) WO2009092276A1 (ru)
ZA (1) ZA201004794B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
EP2492262B1 (en) * 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Fused heterocyclic compound and thrombopoietin receptor activator
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
CN103724206A (zh) * 2014-01-17 2014-04-16 青岛农业大学 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性
WO2015111085A2 (en) * 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
CN104592033A (zh) * 2014-12-30 2015-05-06 杭州和泽医药科技有限公司 一种艾曲波帕关键中间体的合成方法
CN106994120B (zh) * 2016-01-22 2021-05-14 江苏恒瑞医药股份有限公司 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法
TW201726129A (zh) 2016-01-22 2017-08-01 江蘇恆瑞醫藥股份有限公司 一種含有雙環取代吡唑酮偶氮類衍生物或其鹽的藥物組成物及其製備方法
CN108884052A (zh) * 2017-01-19 2018-11-23 江苏恒瑞医药股份有限公司 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体
CN110028497B (zh) * 2018-01-11 2020-11-17 江苏恒瑞医药股份有限公司 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法
CN113226463A (zh) * 2019-01-08 2021-08-06 江苏恒瑞医药股份有限公司 双环取代吡唑酮偶氮类衍生物的给药方案
CN112062699B (zh) * 2020-11-13 2021-02-26 苏州开元民生科技股份有限公司 一种邻氨基苯硫酚的制备方法
WO2022228551A1 (zh) * 2021-04-30 2022-11-03 江苏恒瑞医药股份有限公司 一种血小板生成素受体激动剂的给药方案
WO2023143364A1 (zh) * 2022-01-25 2023-08-03 江苏恒瑞医药股份有限公司 一种血小板生成素受体激动剂的给药方案

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB775216A (en) * 1954-02-23 1957-05-22 Sandoz Ltd Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds
GB806709A (en) * 1955-04-22 1958-12-31 Bayer Ag Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP1961760A3 (en) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
JPH111477A (ja) 1997-06-12 1999-01-06 Hokuriku Seiyaku Co Ltd １，４−ベンゾジアゼピン誘導体及びその用途
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
ATE223608T1 (de) 1998-12-14 2002-09-15 Vodafone Ag Verfahren zur übertragung von verkehrsinformationen
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU6023300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
DE60025632T2 (de) 1999-09-10 2006-08-10 Smithkline Beecham Corp. Thrombopoietin-mimetika
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
ATE344031T1 (de) 1999-12-06 2006-11-15 Smithkline Beecham Corp Thrombopoietin-mimetika
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AR040083A1 (es) * 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
WO2004096154A2 (en) * 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
EP1701934B1 (en) 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
JP4518819B2 (ja) * 2004-03-17 2010-08-04 富士フイルム株式会社 アゾ化合物
EP1845090A4 (en) 2004-12-14 2009-11-11 Nissan Chemical Ind Ltd AMIDE COMPOUND AND THROMBOPOIETINE RECEPTOR ACTIVATOR
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage
AU2006318527A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods

Also Published As

Publication number Publication date
MX2010007553A (es) 2010-10-04
RU2010127786A (ru) 2012-02-20
CN101481352A (zh) 2009-07-15
JP2011509263A (ja) 2011-03-24
BRPI0907234B1 (pt) 2021-08-10
ZA201004794B (en) 2011-09-28
JP5441269B2 (ja) 2014-03-12
HK1134818A1 (en) 2010-05-14
RU2488582C2 (ru) 2013-07-27
CN101679286B (zh) 2011-06-08
ES2533366T3 (es) 2015-04-09
KR20100120141A (ko) 2010-11-12
US8367710B2 (en) 2013-02-05
US20130123507A1 (en) 2013-05-16
BRPI0907234A2 (pt) 2020-08-04
AU2009207966A1 (en) 2009-07-30
KR101556808B1 (ko) 2015-10-01
CN101679286A (zh) 2010-03-24
AU2009207966B2 (en) 2013-03-21
EP2236500A4 (en) 2012-08-22
US20100316601A1 (en) 2010-12-16
EP2236500B1 (en) 2014-12-24
CA2711535C (en) 2015-12-15
PT2236500E (pt) 2015-04-07
CA2711535A1 (en) 2009-07-30
WO2009092276A1 (zh) 2009-07-30
EP2236500A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
UA101172C2 (ru) Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
UA94964C2 (ru) Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
UA99129C2 (ru) Производные оксадиазола и их применение в качестве потенциирующих средств рецепторов глутамата
MY148634A (en) Pyridazinone derivatives
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
GB0607954D0 (en) Organic compounds
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
GEP20125382B (en) New benzamide derivatives as bradykinin antagonists
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2010003495A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas.
IN2012DN03042A (ru)
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MY149649A (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24